Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

KemPharm nets $23.5mm in FOPO

11 Oct 2018

Executive Summary

KemPharm Inc. (pipeline of prodrugs for multiple CNS indications) netted $23.5mm through the public sale of 8.3mm shares at $3. The company plans to use the proceeds to fund its lead extended-release dexmethylphenidate prodrug candidates for attention deficit hyperactivity disorder (ADHD); an NDA submission for KP415 (anticipated Q1 2019); and the initiation of a pivotal trial for preclinical KP484 (expected to begin next year). Earlier this year, KemPharm's first prodrug--abuse-deterrent Apadaz (benzhydrocodone/acetaminophen) for short-term management of acute pain--was approved by the FDA.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By